Search Results

But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn Operating cadence is the quiet force behind biotech momentum, the rhythm that turns intention into real The Pattern: Your “Accidental Cadence” 👉 Every biotech has a cadence. Many early-stage biotechs show the same pattern: strong scientific progress paired with an operating Strategic Takeaway Your biotech is already running on an operating cadence.

Biotech fundraising has undergone a subtle yet significant shift. Clear intellectual property builds confidence on both sides of the biotech fundraising table Why biotech Biotech fundraising rarely fails in the diligence phase itself. In biotech fundraising, coherence builds trust. Strategic Takeaway - Founder Clarity 👉 Biotech fundraising rarely fails because intellectual property

The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where The Pattern: Scientific Isolation Scientific Isolation  = when a biotech’s internal activity becomes Alignment, structure, traction, visibility: these are the forces that pull a biotech out of scientific Most early biotechs think their problem is a lack of data. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

Most biotech pitches don’t fail because the science is weak. A clear biotech pitch answers three key questions immediately. Strong biotech pitches don’t just inform, they align. How to Fix the Gaps 👉 Fixing your biotech pitch doesn’t require a rebrand. A strong biotech pitch isn’t about saying more.

Every biotech founder fears the day the cash runs out. You track the burn rate. Most biotech founders don’t suffer from having the wrong people. Here’s the truth biotech founders miss. Alignment is not a culture topic. A soft skill. ✅ But in biotech, alignment is a multiplier. It’s how biotech companies move from drift to direction.

👉 Biotech startups rarely fail all at once. The difference between surviving and failing in biotech is rarely science. This is a central reason why biotech startups fail . Order does not emerge naturally in biotech. Strategic Takeaway - Why biotech startups fail Biotech startups rarely fail because of a single mistake

It’s a pattern we see far too often in early-stage biotech operations and startups. The 3 Golden Rules of Scientific Thinking — and Why They Break Down in Biotech Operations Leadership   In startups, waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay Scientific thinking will always be your strength, but it must be reshaped to serve your new role. 👉 As a biotech Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

that closed door lit the fuse for a career that would reimagine GPCR therapeutics — and lead to two biotech What followed was a scientific journey that now spans two biotech startups, and a bold reimagining of It was investor rejections, endless slide decks, and the steep learning curve of biotech business. Launching Blue was Ajay’s first hands-on experience with biotech entrepreneurship. Lessons From the Front Lines of Biotech Ajay’s experience in both early-stage biotech and academic science

July 2022 "G.CLIPS biotech is 2 years old today🎂. Looking forward for more 🎊 #team #grateful #biotech #work #birthdaycelebration" Read more at the source

The Gaps They Already See 👉 As a biotech founder, it’s easy to mistake volume for readiness . Clarity, not complexity, is what makes approval possible, and biotech sustainable. The Illusion of Readiness 👉 Many biotech founders walk into a pre-IND meeting with quiet confidence What the FDA Is Actually Optimizing For 👉 Biotech teams often treat the FDA like an evaluator. Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner, Yamina's Corner, biotech development, pharmaceutical, scientific career Hashtags: #DrGPCR #GPCR #DrugDiscovery #Pharmacology #Biotech

For innovators and biotech strategists, stories like Michelle’s reveal how scientific leadership emerges For biotech innovators, those sparks are the future workforce and idea engines.

the architect behind nearly all of Exscientia's partnerships and collaborations across pharma and #biotech⁠

This simple truth applies profoundly to the "go fast" culture in biotech. I work with biotechs, VCs, and CROs to implement the framework that ensures every step forward is strategic

#biotech #lifesciences #appointment #GPCR #Oncology" Read more at the source #DrGPCR #GPCR #IndustryNews

Welcome back GPCR fans, The pace of GPCR innovation is accelerating at a rate that can be difficult to GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

#IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the

2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare

immunology #antibodies #medicine #cancer #innovation #gpcr #synabs #monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals #oncology #healthcare

When the biotech world gathers in Boston, this is where the real conversations begin. Every September, Boston welcomes the global biotech and drug discovery community. Why It Matters Connect with peers across biotech, CROs, and investment who are driving discovery forward Meet both the global biotech community and Boston’s local innovators in one room Be part of Dr. Our mission is simple: bridge science and industry  by connecting researchers, biotech, CROs, and pharma

Beyond Academia: Advising Biotech Carlsson’s collaborative philosophy has also found a place in the biotech It also allows Carlsson to stay plugged into the fast-changing needs of biotech while keeping his academic Biased signaling, allosteric binding sites, and subtype selectivity mean there is rarely a straight line Whether in academia or biotech, the future belongs to research groups that can orchestrate ecosystems And for the next generation of researchers and biotech leaders, that is the real collaboration advantage

Hidden Cost of Good Science Without Systems I’ve seen this pattern again and again—across academia, biotech This is embedded consulting for biotech and VC teams who need to move fast —without compromising scientific Who I Work With ✅ Biotech Teams  – Especially those lacking in-house GPCR leads or overwhelmed by CRO assets in their portfolio. ✅ Contract Research Organizations (CROs)  – Wanting to better align with biotech

GPCR tools and key moves in the biotech world. Dr. Explore this week’s research, tools, and biotech insights in one place.

Corner delivers this week: high-impact insight into GPCR allostery, crafted for pharmacologists and biotech nuance into better decision-making. 🔍 This Week in Premium: Sneak Peek Industry insights:  Strategic biotech This is where funders, peers, and biotech scouts are watching. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Ajay Yekkirala shares the journey from academic pharmacologist to biotech entrepreneur—bridging curiosity Learn entrepreneurial lessons rarely shared with postdocs. When the global biotech crowd lands in Boston for Discovery on Target. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Meanwhile, the industry is moving fast with AI-powered platforms, bold leadership moves, and strategic biotech Explore this week’s research, tools, and biotech insights in one place.

Watch Episode 168 What does it take for a scientist to become a startup leader in biotech? For Dr. often plague probe development. 👉 Learn more about Celtarys’ science-driven solutions on their company page

In this podcast, he lays out the mindset that helped shape products used across biotech and academia—and Dimensions of Discovery pHSense wasn’t built in a vacuum—it was born from decades of groundwork in rare That opened the door to something rare in functional pharmacology: plate-based GPCR internalization tracking Mini Timeline 🎯 Early 2000s: Trinquet leads IP1 & Tag-lite development 🧪 Mid-2010s: Rare-earth scaffold teaming, testing, and failing smarter. 🚀 Why This Matters: Whether you’re launching a tool, starting a biotech